报道３３例类风湿性关节炎（ＲＡ）接受人基因重组干扰素γ治疗的疗效。其中１９例为ＨＬＡ－ＤＲ４阳性，１４例为ＨＬＡ－ＤＲ４阴性。两组的年龄、性别、病程和病期均无显著差异，前者有效率为２６．３％，后者为６４．３％，两组有显著差异（Ｐ＝０．０１３）。两组的副作用无差异。本结果提示ＨＬＡ－ＤＲ４基因可能有影响ＲＡ对药物疗效的作用 Reported 33 cases of rheumatoid arthritis (RA) receiving human recombinant interferon gamma treatment. Of these, 19 were HLA-DR4-positive and 14 were HLA-DR4-negative. There was no significant difference in age, sex, duration of disease and disease between the two groups. The effective rate was 26.3% in the former group and 64.3% in the latter group, with significant difference between the two groups (P = 0.013). There was no difference in side effects between the two groups. The results suggest that HLA-DR4 gene may have an effect on the therapeutic effect of RA